<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>343</serviceExecutionTime><Drug id="56638"><DrugName>fentanyl (sublingual, breakthrough pain), Ethypharm</DrugName><DrugNamesKey><Name id="43087126">Fentanyl ETHYPHARM</Name><Name id="43087189">Recivit</Name><Name id="42757234">fentanyl</Name></DrugNamesKey><DrugSynonyms><Name><Value>fentanyl</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>fentanyl (sublingual, breakthrough pain), Ethypharm</Value></Name><Name><Value>Fentanyl Citrate SL Tablet</Value></Name><Name><Value>Fentanyl ETHYPHARM</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Recivit</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Fentanyl SL</Value></Name><Name><Value>437-38-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="21952">Ethypharm SA</CompanyOriginator><CompaniesPrimary><Company id="16587">Grunenthal GmbH</Company></CompaniesPrimary><CompaniesSecondary><Company id="21952">Ethypharm SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16587" type="Company"><TargetEntity id="4296790654" type="organizationId">Gruenenthal GmbH</TargetEntity></SourceEntity><SourceEntity id="21952" type="Company"><TargetEntity id="4296393444" type="organizationId">Ethypharm SA</TargetEntity></SourceEntity><SourceEntity id="3211" type="ciIndication"><TargetEntity id="G89.3" type="ICD10"/><TargetEntity id="10058019" type="MEDDRA"/><TargetEntity id="-301829128" type="omicsDisease"/><TargetEntity id="6" type="siCondition"/></SourceEntity><SourceEntity id="293" type="Action"><TargetEntity id="271" type="Mechanism">mu-Opioid Agonists</TargetEntity><TargetEntity id="5725" type="Mechanism">mu-Opioid Positive Allosteric Modulators</TargetEntity></SourceEntity><SourceEntity id="PTGT-01361" type="ciTarget"><TargetEntity id="43836512449883" type="siTarget">Mu-type opioid receptor</TargetEntity><TargetEntity id="1032" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Cancer pain - Denmark - Aug-2016</FirstLaunched><FirstLaunched>Cancer pain - France - Aug-2016</FirstLaunched><FirstLaunched>Cancer pain - Netherlands - Aug-2016</FirstLaunched><FirstLaunched>Cancer pain - UK - Aug-2016</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="3211">Cancer pain</Indication></IndicationsPrimary><ActionsPrimary><Action id="293">Opioid receptor mu agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="680">Buccal formulation systemic</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2016-08-31T13:14:39.000Z</LastModificationDate><ChangeDateLast>2017-06-03T00:00:00.000Z</ChangeDateLast><AddedDate>2007-01-16T15:07:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="21952" linkType="Company"&gt;Ethypharm&lt;/ulink&gt;, through marketeer &lt;ulink linkID="16587" linkType="Company"&gt;Grunenthal&lt;/ulink&gt;, has developed a sublingual tablet formulation of fentanyl (Recivit; Fentanyl ETHYPHARM; Fentanyl SL) for the  treatment of breakthrough cancer pain [&lt;ulink linkID="757982" linkType="Reference"&gt;757982&lt;/ulink&gt;], [&lt;ulink linkID="1004037" linkType="Reference"&gt;1004037&lt;/ulink&gt;].  In January 2014, approval was granted to Grunenthal under the EU Decentralised Procedure [&lt;ulink linkID="1792479" linkType="Reference"&gt;1792479&lt;/ulink&gt;]. By August 2016, the drug was available in Denmark, France, Netherlands and the UK [&lt;ulink linkID="1792498" linkType="Reference"&gt;1792498&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By August 2016, the drug was available in Denmark, France, Netherlands and the UK [&lt;ulink linkID="1792498" linkType="Reference"&gt;1792498&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, approval was granted to Grunenthal under the EU Decentralised Procedure [&lt;ulink linkID="1792479" linkType="Reference"&gt;1792479&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, a regulatory filing had been expected in 2011  [&lt;ulink linkID="1226688" linkType="Reference"&gt;1226688&lt;/ulink&gt;], [&lt;ulink linkID="1226703" linkType="Reference"&gt;1226703&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In November 2011, a randomized, placebo-controlled phase III trial (&lt;ulink linkID="126550" linkType="Protocol"&gt;NCT01842893&lt;/ulink&gt;; FYL/24019/008) began which wouild assess the ability of Fentanyl ETHYPHARM to manage breakthrough pain in opioid-treated patients with cancer (expected n = 91) [&lt;ulink linkID="1792172" linkType="Reference"&gt;1792172&lt;/ulink&gt;]. In July 2012 the trial completed [&lt;ulink linkID="1792172" linkType="Reference"&gt;1792172&lt;/ulink&gt;]. In February 2014, data were presented which showed Fentanyl ETHYPHARM couldÂ provided significant improvement in pain intensity compared to placebo as early as 6 minutes post-administration with a sustained effect over 60 minutes, and was  well tolerated [&lt;ulink linkID="1559240" linkType="Reference"&gt;1559240&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2010, the sublingual formulation had been shown to be bioequivalent to &lt;ulink linkID="5254" linkType="Drug"&gt;Actiq&lt;/ulink&gt;, with a lower dose needed to achieve the same plasma concentration of fentanyl as Actiq [&lt;ulink linkID="1175212" linkType="Reference"&gt;1175212&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1792498" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1792498" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1792498" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2016-08-31T00:00:00.000Z</StatusDate><Source id="1792498" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1792254" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1792254" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21952">Ethypharm SA</Company><Country id="FR">France</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1792254" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21952">Ethypharm SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2009-04-28T00:00:00.000Z</StatusDate><Source id="1004037" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16587">Grunenthal GmbH</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1792254" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16587">Grunenthal GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1792254" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16587">Grunenthal GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1792254" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16587">Grunenthal GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1792254" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16587">Grunenthal GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2014-01-27T00:00:00.000Z</StatusDate><Source id="1792479" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21952">Ethypharm SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3211">Cancer pain</Indication><StatusDate>2007-01-16T00:00:00.000Z</StatusDate><Source id="757982" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01361"><Name>Opioid receptor mu</Name><SwissprotNumbers><Swissprot>P33535</Swissprot><Swissprot>P35372</Swissprot><Swissprot>P42866</Swissprot><Swissprot>P79350</Swissprot><Swissprot>P97266</Swissprot><Swissprot>Q5IS39</Swissprot><Swissprot>Q95247</Swissprot><Swissprot>Q95M54</Swissprot><Swissprot>Q9MYW9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>4 references added [&lt;ulink url="utility.reference?i_reference_id=1792476" linkType="reference" linkID="1792476"&gt;1792476&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1792479" linkType="reference" linkID="1792479"&gt;1792479&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1792498" linkType="reference" linkID="1792498"&gt;1792498&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1792254" linkType="reference" linkID="1792254"&gt;1792254&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="16587">Grunenthal GmbH</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21952">Ethypharm SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCC(=O)N(c1ccccc1)C2CCN(CC2)CCc3ccccc3</Smiles></StructureSmiles><Deals><Deal id="162084" title="Grunenthal to distribute Ethypharm's fentanyl sublingual tablets for cancer pain in France, the UK, Belgium, Netherlands, Sweden and Denmark    "/></Deals><PatentFamilies><PatentFamily id="800513" number="WO-2006097361" title="Sublingual coated tablet"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ethypharm SA" id="21952"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>